Bosutinib for pretreated patients with chronic phase chronic myeloid leukemia: primary results of the phase 4 BYOND study

Bosutinib is approved for newly diagnosed Philadelphia chromosome-positive (Ph+) chronic phase (CP) chronic myeloid leukemia (CML) and for Ph+ CP, accelerated (AP), or blast (BP) phase CML after prior treatment with tyrosine kinase inhibitors (TKIs). In the ongoing phase 4 BYOND study (NCT02228382),...

Descripción completa

Detalles Bibliográficos
Autores principales: Hochhaus, Andreas, Gambacorti-Passerini, Carlo, Abboud, Camille, Gjertsen, Bjørn Tore, Brümmendorf, Tim H., Smith, B. Douglas, Ernst, Thomas, Giraldo-Castellano, Pilar, Olsson-Strömberg, Ulla, Saussele, Susanne, Bardy-Bouxin, Nathalie, Viqueira, Andrea, Leip, Eric, Russell-Smith, T. Alexander, Leone, Jocelyn, Rosti, Gianantonio, Watts, Justin, Giles, Francis J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2020
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387243/
https://www.ncbi.nlm.nih.gov/pubmed/32572189
http://dx.doi.org/10.1038/s41375-020-0915-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7387243/
https://www.ncbi.nlm.nih.gov/pubmed/32572189
http://dx.doi.org/10.1038/s41375-020-0915-9

Ejemplares similares